USV is planning to introduce nutraceuticals for enhanced diabetes care, says MD Prashant Tewari
USV partners with Biogenomics to launch biosimilar insulin aspart for diabetes in India
NEW DELHI: Fifty pharmaceutical manufacturing facilities have shuttered their operations in Baddi, Himachal Pradesh, Asia’s largest pharmaceutical hub, while others are operating at significantly reduced capacities after the region was declared a containment zone, raising concerns about the shortage of supply of medicines in the country.
Mumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from NovartisNSE -0.58 % for a deal valued at more than Rs. 200 crore, people aware of the development told ET. The family-run USV is likely to announce the acquisition soon, they said. Emails sent to USV and Novartis did not elicit any response till press time Sunday.
USV Private Limited is planning to invest Rs. 4,000 million in a new formulation plant at Vadodara. USV has three plants based at Daman and Baddi manufacturing Tablets, capsules: sterile injectables & ophthalmic products, one API plant at Chiplun and biotechnology facility in Nerul Mumbai.
FDA investigators, particularly in India, have learned it is best to look beyond the production floor, clean rooms and quality control labs when doing inspections. They look around shredders, in trash cans and even barrels in factory scrap yards.
USV appoints Lowe Lintas as creative agency for SebaMed
USV NA's Generic Octreotide Acetate Receives Approval in US
USV North America's Generic Octreotide Acetate Receives Approval in US
After a year of remediation, an Indian drugmaker has worked its way out from under an FDA warning letter issued for its sterile injectables operation.